This review examines the evolving role of catheter‐based valvular and structural interventions in cancer patients. We sought to answer whether minimally invasive approaches, including transcatheter aortic valve replacement, mitral valve repair, left atrial appendage occlusion, and patent foramen ovale closure, provide safe and effective treatments in high‐risk oncologic populations. Emerging research indicates that these interventions yield comparable short‐term outcomes in cancer and non‐cancer patients, with reduced procedural complications, lower bleeding risks, and improved recovery times. Studies also suggest that careful patient selection and tailored antithrombotic management are critical, as long‐term survival is affected by the underlying malignancy. Our review concludes that catheter‐based interventions offer significant benefits in managing cardiovascular complications in cancer patients. Future investigations should focus on refining selection criteria, optimizing perioperative care, and evaluating long‐term outcomes to enhance interdisciplinary treatment strategies. These findings pave the way for improved care via a tailored approach to patients with both cancer and cardiovascular disease.

The bioresorbable vascular scaffold (BVS) is a promising technology with clear theoretical benefits. Large randomized controlled trials (RCTs) of the early generation of this technology, however, demonstrated issues translating these benefits from the abstract into the clinical realm. This review covers the outcomes beginning with the first-generation scaffolds and provides updates on advances made with newer technologies and evolved approaches to platform delivery. Pooled individual patient data from the ABSORB studies with 5-year follow-up was published in early 2025, showing higher event rates in the BVS group driven by events in the first three years of follow-up. Events after three years were the same or lower compared to traditional metallic drug-eluting stents (DES). BVS technology is not yet ready for clinical primetime. However, there is need for improved scaffold technology and new BVS will again need to be tested against metallic DES in large-scale RCTs with long-term follow-up.

Effusive-constrictive pericarditis (ECP) is a complex clinical condition that combines features of pericardial effusion/tamponade and constrictive pericarditis. The classic hemodynamic definition is persistent elevation of right atrial pressure despite drainage of a pericardial effusion. This review summarizes recent data on its epidemiology, pathophysiology, diagnosis, and management. Prevalence varies from 2.4% to 14.8% depending on diagnostic criteria and etiology, reaching up to 50% in tuberculous pericarditis in endemic regions. Common causes include idiopathic, infectious (particularly tuberculous and bacterial), malignant, and post-surgical etiologies. While invasive hemodynamic assessment remains the reference standard, echocardiography is now the primary diagnostic tool, enabling recognition of constrictive physiology before and after pericardiocentesis. Cardiac magnetic resonance adds complementary information on pericardial thickness, inflammation, and potential for reversibility, aiding therapeutic decisions. Inflammatory ECP frequently resolves with medical therapy (NSAIDs, colchicine, corticosteroids, or IL-1 inhibitors) while tuberculous cases require antimicrobial therapy with corticosteroids in selected patients. ECP is a heterogeneous condition with variable clinical trajectories. Early identification through multimodality imaging is essential to guide therapy, target reversible inflammation, and prevent chronic constriction. Most inflammatory cases respond to anti-inflammatory treatment, whereas pericardiectomy is reserved for persistent, irreversible constrictive physiology despite optimal medical therapy.

This review summarizes current applications of artificial intelligence (AI) in multimodality cardiac imaging for the evaluation of valvular heart disease (VHD). The prevalence of VHD continues to rise, placing increasing demands on cardiovascular imaging and longitudinal management. AI systems have been applied across echocardiography, cardiac computed tomography (CCT), and cardiac magnetic resonance (CMR) to automate image classification, segmentation, disease detection, and severity assessment. The most mature AI models have centered on transthoracic echocardiography (TTE), where deep learning (DL) frameworks enable whole-study interpretation and preliminary report generation. Applications in CCT and CMR remain in earlier stages but show promise for segmentation, tissue characterization, and pre-procedural planning. AI has the potential to enhance the accuracy, reproducibility, and efficiency of imaging-based VHD assessment. Key challenges remain around generalizability, transparency, and clinical integration. Multidisciplinary collaboration is essential to ensure that AI complements, rather than replaces, human expertise.

Epicardial adipose tissue (EAT), the visceral fat of the heart, is highly inflammatory fat depot with pro-inflammatory transcriptome and proteosome. EAT contributes to the development and progression of coronary artery disease (CAD) and atrial fibrillation (AF) through multifactorial inflammatory pathways. However, the paradigm linking EAT inflammation and cardiovascular risk was recently reevaluated. EAT inflammation may be also necessary process for adipose tissue remodeling and expansion to accommodate excess lipids. EAT inflammation may be also considered an adaptive response of adipose tissue to the effects of glucagon-like peptide-1 receptor (GLP-1Rs) and glucose-dependent insulinotropic polypeptide (GIP) analogs. The presence of GLP-1 (GLP-1R) and GIP receptors (GIP-R) suggest direct interaction of these agents with EAT. EAT GLP-1R and GIP-R activation can induce a beneficial balance between increased adipogenesis and reduced ectopic fat accumulation. Cardiovascular effects of liraglutide, semaglutide and tirzepatide can be mediated by EAT inflammation.

Ultrasound-targeted microbubble cavitation (UTMC) has emerged as a transformative non-invasive technology in diagnostic imaging, therapy, and targeted gene and drug delivery. As UTMC advances toward clinical translation, understanding its impact on fundamental cellular functions is essential. Recent studies on UTMC have provided insights into its effects on biological processes. These include transient membrane opening and resealing (sonoporation), calcium ion (Ca2+) influx, generation of free radicals, nitric oxide synthesis, cytoskeletal remodeling, inter-endothelial gap formation, gene expression changes, and neuroinflammation. This review explores the mechanisms underlying UTMC, with a focus on ultrasound-targeted microbubble cavitation and its bioeffects on cellular function. We examine the molecular processes induced by cavitation, including sonoporation and Ca2+ influx, and highlight their effects on key biological processes.

To provide an overview of human induced pluripotent stem cell (hiPSC)-derived cardiovascular lineages and describe their impact on drug testing in vitro. hiPSCs have garnered tremendous interest over the last decade due to their potential for unlimited proliferation and differentiation into cardiovascular lineages. Technologies using tissue engineering, 3D bioprinting, and organ-on-a-chip platforms composed of hiPSC derivatives can produce cardiovascular tissue mimetics that enhance drug screening applications. hiPSC-derived cardiovascular lineages advance drug screening efforts by using autologous cells that are more therapeutically relevant. Established approaches to reproducibly generate hiPSC-derived cardiovascular lineages and their subsequent organization into 3D constructs more accurately mimic the physiological organization of cardiac tissue, leading to improved identification of potential drug targets for therapeutic testing.